This is an interesting article further confirming the popular usage of a SPAC to enter the public markets. In this case, the timing is well positioned - prior to a hopeful launch of a biosimilar version of Abbvie's Humira.

Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut

‍